Opus Genetics, Inc. IRD
NASDAQ · United States · Health Technology
$4.58+0.07 (+1.55%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Opus Genetics, Inc. (NASDAQ:IRD) reported on September 9 that all five low-dose BIRD-1 participants showed clinically meaningful improvement on at least one visual-function measure after treatment with investigational gene therapy OPGx-BEST1. The open-label Phase 1/2 cohort included three participants with Best vitelliform macular dystrophy followed for three months and two with autosomal recessive bestrophinopathy followed […]
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State S
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.